|
|
Office Locations:
|
590 Madison Avenue, 21st floor
New York, NY 10022
Phone: 212-521-4379
Fax: 212-692-6072
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Valence Life Sciences is a leading life sciences investment firm focused on late-stage private and micro-cap public drug development companies. Valence Advantage Life Sciences Fund II was established in 2012 by Managing Directors, Eric W. Roberts and A. Rachel Leheny, Ph.D.-- one of Wall Street's premier life sciences investment banking and research teams. Fund II is the successor to Caxton Advantage Life Sciences Fund I which Mr. Roberts and Dr. Leheny began investing in 2006 with the same investment strategy. Valence Advantage Life Sciences was formed as an entity independent of an affiliate of Caxton Associates, a New York-based trading and investment firm. Dr. Leheny, Mr. Roberts and their team will continue to manage Caxton Advantage's nine portfolio companies. The team draws on over 25 years of expertise.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
